A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

• Main Authors: José Manuel Ramos-Rincón (Author), Héctor Pinargote-Celorio (Author), Jara Llenas-García (Author), Oscar Moreno-Pérez (Author), Inmaculada González-Cuello (Author), Pilar Gonzalez- (Author), Belén Martínez-López (Author), Sergio Reus (Author), María García-López (Author), Juan Carlos Rodríguez (Author), Vicente Boix (Author), Esperanza Merino (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: The evidence for remdesivir therapy in immunocompromised patients is scarce. To evaluate remdesivir (RDV) effectiveness and safety in COVID-19 outpatients at high risk for progression in a real-world setting, we compare the outcome in immunocompromised (IC) patients with that in non-im...